Jo Chan-Woo, Park Chan-Hee, Lee Jong-Hyug, Kim Ji-Hun
Department of Pediatric Dentistry, Wonju Severance Christian Hospital, Yonsei University, Wonju, Korea.
Department of Dentistry, Wonju College of Medicine, Yonsei University, Wonju, Korea.
J Dent Anesth Pain Med. 2017 Jun;17(2):157-161. doi: 10.17245/jdapm.2017.17.2.157. Epub 2017 Jun 29.
In sedation via the submucosal route, the drug is administered through the maxillary buccal submucosa. It is time saving, effective, and safe. Patients with autism, a mental disorder, often find it hard to make relationships with other people. These patients display a strong resistance to dental treatment and sedation. This study reports a successful case of behavioral management during dental treatment, using sedation via the submucosal route. The patient was strongly resistant to sedation via the oral, intramuscular, and intravenous routes. The drug used was 9 mg (0.1 mg/kg) of midazolam. Through this case report, we reaffirm the significance of sedation via the submucosal route, and expect that it will be used more frequently for patients with autism, who display behaviors that are difficult to manage, patients with other disabilities, and children.
在通过黏膜下途径进行镇静时，药物通过上颌颊侧黏膜下给药。这种方法省时、有效且安全。患有自闭症（一种精神障碍）的患者通常很难与他人建立关系。这些患者对牙科治疗和镇静表现出强烈的抗拒。本研究报告了一例在牙科治疗期间通过黏膜下途径进行镇静的行为管理成功案例。该患者对口服、肌肉注射和静脉注射镇静均有强烈抗拒。使用的药物是9毫克（0.1毫克/千克）咪达唑仑。通过本病例报告，我们重申了黏膜下途径镇静的重要性，并期望它能更频繁地用于患有难以管理行为的自闭症患者、其他残疾患者和儿童。
